Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma

por Skalicky, Anne M., Ghate, Sameer R., Perez, Jose Ricardo, Rentz, Anne M.
Publicado 2017

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line...

por Swallow, Elyse, Messali, Andrew, Ghate, Sameer, McDonald, Evangeline, Duchesneau, Emilie, Perez, Jose Ricardo
Publicado 2018

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospecti...

por Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Li, Nanxin, Swallow, Elyse, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Publicado 2018

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

por Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Swallow, Elyse, Li, Nanxin, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Publicado 2017